Post by icemandios on Nov 22, 2017 15:28:46 GMT
Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference
BOULDER, Colo., Nov. 22, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event:
Piper Jaffray Healthcare Conference
Presenter:
Ron Squarer, Chief Executive Officer
Date:
Wednesday, November 29, 2017
Time:
9:00 a.m. Eastern Time
Webcast:
event.webcasts.com/starthere.jsp?ei=1171462&tp_key=889917fd39
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
BOULDER, Colo., Nov. 22, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event:
Piper Jaffray Healthcare Conference
Presenter:
Ron Squarer, Chief Executive Officer
Date:
Wednesday, November 29, 2017
Time:
9:00 a.m. Eastern Time
Webcast:
event.webcasts.com/starthere.jsp?ei=1171462&tp_key=889917fd39
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
